520000login-checkCareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care |
AUGUST, 02, 2022
AlloHome Alerts Healthcare Provider of Adverse Events to Drive Earlier Interventions
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the availability of AlloHome™, a pan-organ patient monitoring solution that extends care into a patient’s home by capturing a range of vital health data that can help doctors with the early identification of adverse clinical events and the ability to make preemptive measures to avoid complications pre- and post-transplantation.
Read the full press release at CareDx.com.
520000login-checkCareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care |